STAAR Surgical Showcases EVO ICL Innovation and Clinical Insights
Expanded indications, surgeon-led education, and new clinical research highlight STAAR Surgical’s presence at the ESCRS Congress
Clinical Scorecard: STAAR Surgical Showcases EVO ICL Innovation and Clinical Insights
At a Glance
| Category | Detail |
|---|
| Condition | Myopia and Astigmatism Correction |
| Key Mechanisms | Implantable Collamer® Lens (ICL) technology designed for optical quality and biocompatibility. |
| Target Population | Patients up to 60 years of age, including those needing supplemental lenses after cataract surgery. |
| Care Setting | Clinical practice and surgical settings. |
Key Highlights
- Over four million EVO ICLs sold worldwide.
- EVO ICL received CE Mark approval in Europe in 2011.
- Expanded indications for use include patients up to 60 years and as a piggyback lens.
- EVO Insights LIVE program facilitates peer-to-peer discussions among surgeons.
- EVO ICL technology allows for lens removal or exchange based on visual needs.
Guideline-Based Recommendations
Diagnosis
- Assessment of myopia and astigmatism for potential ICL candidates.
Management
- Postoperative management and evaluation of vault and centration.
Monitoring & Follow-up
- Long-term outcomes and visual quality assessments post-ICL implantation.
Risks
- Consideration of vault-related complications and lens exchange criteria.
Patient & Prescribing Data
Individuals with myopia and astigmatism, including those post-cataract surgery.
EVO ICL provides an alternative to corneal laser procedures without tissue removal.
Clinical Best Practices
- Utilize peer-to-peer discussions for troubleshooting and management strategies.
- Evaluate ciliary sulcus anatomy for optimal ICL placement.
- Consider patient-specific visual needs when deciding on lens exchange.
Related Resources & Content
